 |
|
|
| |
Risk and Predictors of Mortality or Hepatocellular Carcinoma among Entecavir- or Adefovir-Treated Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation
|
| |
| |
Reported by Jules Levin
Apr 14-18 Vienna Austria,
45th Annual Meeting of the European Association for Study of the Liver, 2010
Yun-Fan Liaw1, Maria Raptopoulou-Gigi2, Hugo Cheinquer3, Shiv Kumar Sarin4, Tawesak Tanwandee5, Nancy Leung6, Cheng-Yuan Peng7, Robert P. Myers8, Robert S. Brown Jr9, Naoky Tsai10, Jolanta Bialkowska11, Shijie Tang12, Elizabeth Cooney12
1Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan; 2Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil; 4Department of Gastroenterology, G. B. Pant Hospital, New Delhi, India; 5Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 6Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China;
7China Medical University Hospital, Taichung, Taiwan; 8Liver Unit, University of Calgary, Alberta, Canada; 9Center for Liver Disease and Transplantation, Columbia University Medical Center, New York, USA; 10John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii. 11Department of Infectious Diseases, Medical University, Lodz, Poland; 12Research & Development, Bristol-Myers Squibb Company, Wallingford, USA
Background
The reported 5-year survival of patients with decompensated cirrhosis is 14%, compared to 84% for patients with compensated cirrhosis1
In chronic hepatitis B (CHB) patients with decompensated liver disease, suppression of viral
replication with antiviral therapy has been shown to result in clinical improvement and
increased survival2,3
In CHB patients with compensated liver disease, long-term entecavir (ETV) therapy resulted in durable suppression of viral replication and regression of fibrosis/cirrhosis4
Long-term adefovir (ADV) therapy has also been associated with regression of fibrosis5
|
| |
|
|
|
|
|
